Syndicated Report

Pulmonary Arterial Hypertension Causes and Treatments

February 12, 2019

Research Objectives:

  • Understand the current pulmonary arterial hypertension (PAH) patient and treatment landscape
  • Explore physician understanding of new treatments in development for PAH and their expectations

Methodology:
Method: 8-minute MicroSurvey via InCrowd
Crowds: US Cardiologists, US Pulmonologists
Sample Size: n=50
Fielding Period: January 30, 2019
Screening Criteria: Qualified respondents are US-based Dermatologists who…
• Have at least five PAH patients under their care
• Are aware of products in development for the treatment of PAH

One key finding:
Most physicians feel that increased patient survival, improved health-related quality of life, and improved functional class are the most important clinical trial endpoints for new PAH treatments.
Almost half of physicians agree that the ideal mechanism of action (MOA) for new PAH drugs in development should be selective pulmonary vasodilation

Download the full report now!

  • This field is for validation purposes and should be left unchanged.